knowledge -WSS

knowledge

author：explore 2025-08-04 04:18:03 - browse：1373

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Health tech investors get more selective as pandemic boom fades

WSS

Medicare drug price lawsuits could be good politics for Biden

Mass General, Mayo Clinic look to monetize custom

Readout LOUD podcast: Live from the 2023 STAT Summit

Is there really a nursing shortage in the U.S.?

Inaction leaves children at risk from dangerous chemotherapy drug

To bolster infectious disease surveillance, genomics powerhouses team up

focus

knowledge

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Microsoft launches AI tool for clinical documentation through Epic

Supreme Court strikes down use of affirmative action

What causes osteoarthritis? Researchers study link to brain protein

Trump demands the U.S. pay no more for drugs than other countries … again

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Moonlake's readout produced a cash windfall. Risks remain

Head of FDA's diagnostics center, who led through Covid, retires

Heart attack and stroke risk calculators need revising

Update the Apgar Score to remove skin color

leisure time

STAT Readout Newsletter: Biotech news today

Cardiologists urge adding sexual orientation, gender identity to health records

Roivant's CEO is a star, but biotech's black hole persists

Readout LOUD podcast: Live from the 2023 STAT Summit

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

ADCs take center stage as promising cancer treatments

hotspot

leisure time

entertainment

entertainment